Safety and Efficacy of Treatment with Daily Sofosbuvir 400 mg + Ribavirin 200 mg for 24 Weeks in Genotype 1 or 3 HCV-Infected Patients with Severe Renal Impairment

被引：0

作者：

Martin, Paul ^{[2
]}

Gane, Edward J. ^{[3
]}

Ortiz-Lasanta, Grisell ^{[4
]}

Liu, Lin ^{[1
]}

Sajwani, Karim ^{[1
]}

Kirby, Brian ^{[1
]}

Denning, Jill M. ^{[1
]}

Stamm, Luisa M. ^{[1
]}

Brainard, Diana M. ^{[1
]}

McHutchison, John G. ^{[1
]}

Lawitz, Eric ^{[5
]}

Gordon, Stuart C. ^{[6
]}

Robson, Richard A. ^{[7
]}

机构：

[1] Gilead Sci, Raleigh, NC USA

[2] Univ Miami, Coral Gables, FL 33124 USA

[3] Univ Auckland, Auckland 1, New Zealand

[4] Fundc Invest, San Juan, PR USA

[5] Texas Liver Inst, San Antonio, TX USA

[6] Henry Ford Hlth Syst, Detroit, MI USA

[7] Christchurch Clin Studies Trust Ltd, Christchurch, New Zealand

来源：

关键词：

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

1128

引用

页码：765A / 766A

页数：2